Hanlon Investment Management’s AbbVie ABBV Stock Holding History

Hanlon Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$482K	Buy	2,215 +138	+7%	+$30.6K	0.27%	129
2025 Q4	$475K	Buy	2,077 +265	+15%	+$60.4K	0.26%	127
2025 Q3	$420K	Buy	1,812 +300	+20%	+$61.1K	0.25%	131
2025 Q2	$281K	Sell	1,512 -93	-6%	-$17.3K	0.2%	142
2025 Q1	$336K	Sell	1,605 -529	-25%	-$103K	0.25%	123
2024 Q4	$379K	Buy	2,134 +774	+57%	+$142K	0.1%	130
2024 Q3	$269K	Buy	1,360 +180	+15%	+$33.6K	0.08%	141
2024 Q2	$202K	Buy	+1,180	New	+$195K	0.06%	156
2023 Q2	–	Sell	-7,932	Closed	-$1.26M	–	129
2023 Q1	$1.26M	Sell	7,932 -58	-0.7%	-$8.87K	0.38%	48
2022 Q4	$1.29M	Buy	7,990 +138	+2%	+$21.2K	0.44%	48
2022 Q3	$1.05M	Buy	+7,852	New	+$1.13M	0.4%	51
2017 Q2	–	Sell	-42,872	Closed	-$2.79M	–	27
2017 Q1	$2.79M	Buy	+42,872	New	+$2.7M	0.35%	38
2016 Q3	–	Sell	-73,216	Closed	-$4.53M	–	52
2016 Q2	$4.53M	Buy	+73,216	New	+$4.46M	0.39%	80
2016 Q1	–	Sell	-64,598	Closed	-$3.83M	–	75
2015 Q4	$3.83M	Buy	+64,598	New	+$3.72M	0.36%	61

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hanlon Investment Management's ABBV Position: Q1 2026 in Review

Hanlon Investment Management increased its AbbVie (ABBV) stake by 6.6% in Q1 2026, buying an estimated $30.6K and bringing the position to 2,215 shares worth $482K. The position accounts for 0.27% of the portfolio, ranked #129.

Hanlon Investment Management first reported a position in ABBV in Q4 2015 and has held it in 14 quarters since. The position peaked at $4.53M in Q2 2016. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Hanlon Investment Management held 2,215 shares of AbbVie worth $482K as of Q1 2026.
Hanlon Investment Management bought 138 AbbVie shares in Q1 2026, an estimated $30.6K.
AbbVie made up 0.27% of Hanlon Investment Management's portfolio in Q1 2026, its #129 holding.
Hanlon Investment Management first reported a position in AbbVie in Q4 2015 and has held it in 14 quarters since.
Hanlon Investment Management's AbbVie position peaked at $4.53M in Q2 2016.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Hanlon Investment Management's 13F filing for Q1 2026, filed 12 May 2026.